A retrospective, cohort study of ranibizumab in patients with Neovascular age-related macular degeneration
Phase of Trial: Phase IV
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 31 Jan 2017 Primary endpoint (Mean change in visual acuity (VA) from baseline to month 12.) has been met according to the results published in the Advances in Therapy.
- 31 Jan 2017 Results published in the Advances in Therapy.